|
EMA Allows Biosimilar Sponsors to Reference Non-EU Products in Applications
The European Medicines Agency (EMA) will soon allow biosimilars sponsors to reference biologics made outside the European Economic Area (EEA) in some preclinical and clinical studies required for approval.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives